Association between red cell distribution width and response to methotrexate in rheumatoid arthritis

  • M. Bellan | mattia.bellan@med.uniupo.it Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.
  • D. Soddu Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy.
  • E. Zecca Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy.
  • A. Croce Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy.
  • R. Bonometti Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy.
  • R. Pedrazzoli Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.
  • D. Sola Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.
  • C. Rigamonti Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.
  • L.M. Castello Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.
  • G.C. Avanzi Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.
  • M. Pirisi Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.
  • P.P. Sainaghi Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; Division of Internal Medicine, Immunorheumatology Unit, CAAD (Center for Translational Research on Autoimmune and Allergic Disease) Maggiore della Carità Hospital, Novara, Italy; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.

Abstract

Red cell distribution width (RDW) is an unconventional biomarker of inflammation. We aimed to explore its role as a predictor of treatment response in rheumatoid arthritis (RA). Eighty-two RA patients (55 females), median age [interquartile range] 63 years [52-69], were selected by scanning the medical records of a rheumatology clinic, to analyze the associations between baseline RDW, disease activity scores and inflammatory markers, as well as the relationship between RDW changes following methotrexate (MTX) and treatment response. The lower the median baseline RDW, the greater were the chances of a positive EULAR response at three months, 13.5% [13.0-14.4] being among those with good response, vs 14.0% [13.2-14.7] and 14.2% [13.5- 16.0] (p=0.009) among those with moderate and poor response, respectively. MTX treatment was followed by a significant RDW increase (p<0.0001). The increase of RDW was greater among patients with good EULAR response, becoming progressively smaller in cases with moderate and poor response (1.0% [0.4-1.4] vs. 0.7 [0.1-2.0] vs. 0.3 [-0.1-0.8]; p=0.03). RDW is a strong predictor of early response to MTX in RA. RDW significantly increases after MTX initiation in parallel to treatment response, suggesting a role as a marker of MTX effectiveness.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-04-10
Info
Issue
Section
Articles
Keywords:
Red cell distribution width, rheumatoid arthritis, methotrexate, biomarker.
Statistics
  • Abstract views: 270

  • PDF: 157
How to Cite
Bellan, M., Soddu, D., Zecca, E., Croce, A., Bonometti, R., Pedrazzoli, R., Sola, D., Rigamonti, C., Castello, L., Avanzi, G., Pirisi, M., & Sainaghi, P. (2020). Association between red cell distribution width and response to methotrexate in rheumatoid arthritis. Reumatismo, 72(1), 16-20. https://doi.org/10.4081/reumatismo.2020.1243